Fibrin specificity of plasminogen activators, rebound generation of thrombin, and their therapeutic implications

Coronary Artery Disease

Volumn 12, Issue 4, 2001, Pages 323-332

  Sobel, Burton E ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b University of Vermont Colchester Research Facility   (United States)

Author keywords

Coronary thrombolysis; Fibrin specificity; Fibrinolysis; Procoagulant effects of plasminogen activators

Indexed keywords

ALTEPLASE; ANISTREPLASE; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; LANOTEPLASE; PLASMINOGEN ACTIVATOR; RETEPLASE; STREPTOKINASE; TENECTEPLASE; UROKINASE;

ANTICOAGULATION; BINDING SITE; BLOOD CLOT LYSIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; NOMENCLATURE; PARTIAL THROMBOPLASTIN TIME; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN BINDING; REBOUND; REVIEW; THROMBOGENESIS;

ANIMALS; ANTICOAGULANTS; ASPIRIN; BLOOD COAGULATION; DOGS; FIBRIN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; RABBITS; TERMINOLOGY; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034969978     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200106000-00009     Document Type: Review

References (78)

1. The language of lysis: A proposal to standardize the nomenclature
2. Carboxypeptidases: New regulators of plasminogen activation in vivo?
3. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis
4. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA)
5. Paradoxical attenuation of fibrinolysis attributable to 'plasminogen steal' and its implications for coronary thrombolysis
6. Coronary thrombolysis: Editorial overview
7. Influence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro
8. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction
9. Clot-selective compared with nonselective fibrinolytic drugs: Déjà vu - All over again
10. Randomized double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence
11. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
12. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
13. Evidence-based medicine and reteplase: Inductive arguments over deductive reasoning
14. Treatment of acute Q wave myocardial infarction
15. Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA)
16. Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology
17. Is time running out on streptokinase?
18. Efficacy of streptokinase but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment
19. Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The Second National Registry of Myocardial Infarction)
20. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2)
21. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction
22. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction
23. Sixty-minute alteplase protocol: A new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction
24. Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro
25. Recombinant staphylokinase variants with altered immunoreactivity IV: Identification of variants with reduced antibody induction but intact potency
26. Recombinant staphylokinase variants with altered immunoreactivity III: Species variability of antibody binding patterns
27. Staphylokinase: A potent uniquely fibrin-selective thrombolytic agent
28. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction
29. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction
30. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase
31. A faster-acting and more potent form of tissue plasminogen activator
32. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction. Results of the TIMI 10B trial
33. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial
34. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
35. The relative rapidity of recanalization indued by recombinant tissue-type plasminogen activator (r-tPA) and TNK-tPA, assessed with enzymatic methods
36. Early detection of myocardial infarction in conscious dogs by analysis of plasma MM creatine kinase isoforms
37. Prompt detection of coronary recanalization by analysis of rates of change of concentrations of macromolecular markers in plasma
38. Detection of repulsion within one hour after coronary recanalization by analysis of isoforms of the MM creatine kinase isoenzyme in plasma
39. Strokes, statistics, and sophistry in trials of thrombolysis for acute myocardial infarction
40. Conjunctive therapy for thrombolysis
41. How does the coagulation system really work and why should we care?
42. A model for the tissue factor pathway to thrombin I. An empirical study
43. Acute coronary syndromes: 1. The platelet's role
44. Acute coronary syndromes: 2. Antiplatelet agents
45. Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions
46. Plasmin-mediated activation of contact system in response to pharmacologic thrombolysis
47. Thrombolytic therapy in acute myocardial infarction. Comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin
48. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs
49. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model
50. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombolysis
51. HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: Results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte
52. Intracranial bleeding fibrinolysis and anticoagulation: Causal connections and clinical imprications
53. Thrombin generation inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: Results from the GUSTO-I Trial
54. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GP IIb/IIIa antibody
55. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model
56. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase
57. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin
58. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction
59. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes
60. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: Results of the Heparin in Early Patency (HEAP) Pilot Study
61. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: The Heparin in Early Patency (HEAP) randomized trial
62. Novel anticoagulants based on inhibition of the factor VIIa/tissue factor pathway
63. Novel antithrombotics based on modulation of the protein C pathway
64. Novel approaches to thrombolysis based on modulation of endogenous fibrinolysis
65. Thrombolytic therapy and proteolysis of factor V
66. A novel bedside tissue factor-dependent clotting assay permitting improved assessment of both antithrombotic and antiplatelet therapy
67. Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications
68. Aspirin augmentation of the efficacy of thrombolysis
69. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody ibn a canine preparation
70. Increased platelet reactivity in patients given Orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy
71. Differential effects of anticoagulants on the activation of platelets ex vivo
72. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects
73. Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: A potential contributor to cardiovascular risk
74. Use of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock
75. Thrombolysis plus aortic counterpulsation: Improved survival in patients who present to community hospitals with cardiogenic shock
76. Angioplasty or thrombolysis: Misconstrued questions and misleading answers
77. Conundrums in coronary thrombolysis: The TIMI-II/TIMI-III flow dichotomy and the denominator problem
78. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT Angioplasty Compatibility Trial